A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice

  • J Med Chem. 2013 Jul 11;56(13):5553-61. doi: 10.1021/jm4005708.
Yujun Zhao  1 ,  Shanghai Yu ,  Wei Sun ,  Liu Liu ,  Jianfeng Lu ,  Donna McEachern ,  Sanjeev Shargary ,  Denzil Bernard ,  Xiaoqin Li ,  Ting Zhao ,  Peng Zou ,  Duxin Sun ,  Shaomeng Wang
Affiliations
  • 1. Comprehensive Cancer Center and Departments of Internal Medicine, Pharmacology, and Medicinal Chemistry, University of Michigan , Ann Arbor, Michigan 48109, United States.
PMID: 23786219 DOI: 10.1021/jm4005708
Abstract

We previously reported the discovery of a class of spirooxindoles as potent and selective small-molecule inhibitors of the MDM2-p53 interaction (MDM2 inhibitors). We report herein our efforts to improve their pharmacokinetic properties and in vivo antitumor activity. Our efforts led to the identification of 9 (MI-888) as a potent MDM2 Inhibitor (Ki = 0.44 nM) with a superior pharmacokinetic profile and enhanced in vivo efficacy. Compound 9 is capable of achieving rapid, complete, and durable tumor regression in two types of xenograft models of human Cancer with oral administration and represents the most potent and efficacious MDM2 Inhibitor reported to date.

Products